Diltiazem Hydrochloride Controlled Release Capsules

Pharmacological action: This product is a calcium channel blocker, and its action is related to the inhibition of calcium ion influx during myocardial and vascular smooth muscle depolarization. This product can effectively dilate the epicardial and subendocardial coronary arteries, relieve spontaneous angina pectoris or angina pectoris caused by coronary artery spasm induced by ergonovine; by slowing down the heart rate and lowering blood pressure, it can reduce myocardial oxygen demand, increase exercise tolerance and relieve exertional angina pectoris. This product can relax vascular smooth muscle, reduce peripheral vascular resistance and blood pressure; the extent of blood pressure reduction is related to the degree of hypertension, and only slightly reduces blood pressure in normal blood pressure patients. This product has a negative inotropic effect and can slow down the conduction of the sinoatrial node and atrioventricular node. Toxicological effects: Carcinogenic, mutagenic and reproductive toxic effects have been reported. No carcinogenic effect was found in rats taking this product for 24 months and in mice taking this product for 21 months. No mutagenic effect was found in in vitro bacterial experiments. Animal experiments have confirmed that this product has no significant effect on fertility.

The main ingredient of this product is diltiazem hydrochloride.

This product is a capsule, and the contents are small white particles.

Preventive treatment of stable angina pectoris and hypertension.

Oral administration, once a day, one tablet each time.

Common adverse reactions: edema, headache, nausea, dizziness, rash, weakness. Rare adverse reactions (<1%): Cardiovascular system: angina pectoris, arrhythmia, atrioventricular block, bradycardia, bundle branch block, congestive heart failure, abnormal electrocardiogram, hypotension, palpitations, syncope, tachycardia, ventricular premature beats. Nervous system: dreaming, amnesia, depression, abnormal gait, hallucinations, insomnia, nervousness, paresthesia, personality changes, drowsiness, tremor. Digestive system: anorexia, constipation, diarrhea, dysgeusia, indigestion, thirst, vomiting, weight gain, mild increase in alkaline phosphatase, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase. Skin: petechiae, photosensitivity, itching, urticaria. Others: amblyopia, increased CPK, dry mouth, dyspnea, epistaxis, irritability

1. Patients with sick sinus syndrome without pacemaker. 2. Patients with II or III degree atrioventricular block without pacemaker. 3. Patients with systolic blood pressure lower than 12kPa (90mmHg). 4. Patients allergic to this product. 5. Patients with acute myocardial infarction or pulmonary congestion.

1 beta-receptor blockers: Studies have shown that diltiazem hydrochloride is well tolerated when used in combination with beta-receptor blockers, but there is insufficient data in patients with left ventricular dysfunction and conduction dysfunction. This product can increase the bioavailability of propranolol by nearly 50%, so the dose of propranolol needs to be adjusted when starting or stopping the combination of the two drugs. 2 Cimetidine: Due to the inhibition of cytochrome P450 oxidase, the first-pass metabolism of this product can be affected, which can significantly increase the peak blood concentration of this product and the area under the drug-time curve. Ranitidine only slightly increases the blood concentration of this product. 3 Digoxin: There are reports that this product can increase the blood concentration of digoxin by 20%, but there are also reports that it has no effect. Although the results are contradictory, the blood concentration of digoxin should be monitored when starting, adjusting and stopping treatment with this product to avoid excessive or insufficient digoxin. 4 Anesthetics: They have inhibitory effects on myocardial contraction, conduction, and automaticity, and have vasodilation effects, which can produce synergistic effects with this product. Therefore, the dose must be carefully adjusted when the two drugs are used together. 5 Benzodiazepines: This product can significantly increase the peak plasma concentration of triazolam and midazolam and prolong their elimination half-life. 6 Carbamazepine: After this product is used in combination with carbamazepine, the blood concentration of carbamazepine can increase by 40-72% in some cases, leading to toxicity. 7 Cyclosporine: It was found in heart and kidney transplant patients that when this product is used in combination with cyclosporine, the dose of cyclosporine should be reduced by 15-48% to ensure that the drug concentration of cyclosporine is the same as before the combination of this product. The plasma drug concentration of cyclosporine should be monitored when the two are used in combination, especially when starting, adjusting the dose, or stopping the use of this product. The effect of cyclosporine on the plasma drug concentration of this product is unknown. 8 Rifampicin: After this product is used in combination with rifampicin, the plasma drug concentration and efficacy of this product can be significantly reduced.

Keep in a light-proof and airtight container.

120mg

Guangdong Baiao Pharmaceutical Co., Ltd.

• Founded in:

  2002-06-05

• Address:

  No. 4-1, Biaohai Industrial Zone, Shatang Town, Kaiping City

• Tax NO.:

  91440783737598158B

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view